The government on Friday, 17 April removed restrictions on exports of medicines made from Paracetamol amid the outbreak of COVID-19.
However, restrictions on exports of Paracetamol active pharmaceutical ingredients (APIs or raw materials) will continue, the Directorate General of Foreign Trade (DGFT) said in a notification.
To export a product, which is under restricted category, an exporter requires no-objection certificate or permission of a licence from the DGFT.
"...The formulations made from Paracetamol (including fixed-dose combinations)...are made free for export with immediate effect. However, Paracetamol APIs will remain restricted for export," it said.
The government on 3 March had put export restrictions on 26 pharma ingredients and medicines, including paracetamol.
However on 6 April, it removed the export restrictions on 24 APIs and formulations excluding Paracetamol. India exported formulations made from Paracetamol worth USD 5.41 billion during April-January 2019-20. It was USD 5.8 billion in 2018-19.
According to Mumbai-based doctor Sachin Ramteke, Paracetamol is used commonly to treat body pain and fever.
"It is used as symptomatic treatment to control body temperature," he said.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)